AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aktis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $835.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$15.07 (+37,675%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $835.58M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.72
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $8.77
- Diluted shares
- 55M
Two years at a glance
Fiscal years 2024 to 2025, USD
Reported period